ImmunityBio (IBRX) Cash & Current Investments (2013 - 2026)

ImmunityBio (IBRX) has 14 years of Cash & Current Investments data on file, last reported at $380.9 million in Q1 2026.

• Cash & Current Investments for Q1 2026 came in at $380.9 million, up 518.4% year-over-year; the trailing twelve-month figure through Mar 2026 was $380.9 million (up 518.4% YoY), and the FY2025 annual result was $242.8 million, up 62.09% from the prior year.
• Cash & Current Investments advanced to $380.9 million in Q1 2026 per IBRX's latest filing, from $242.8 million in the prior quarter.
• Over five years, Cash & Current Investments peaked at $380.9 million in Q1 2026 and troughed at $46.0 million in Q2 2023.
• A 5-year average of $167.8 million and a median of $153.7 million in 2025 frame the typical range for Cash & Current Investments.
• The sharpest annual moves came in 2022 and 2026: Cash & Current Investments slumped 66.2% in 2022, then jumped 518.4% in 2026.
• A 5-year view of Cash & Current Investments shows it stood at $107.2 million in 2022, then jumped by 148.6% to $266.5 million in 2023, then slumped by 43.78% to $149.8 million in 2024, then jumped by 62.09% to $242.8 million in 2025, then jumped by 56.86% to $380.9 million in 2026.
• Business Quant data shows IBRX's Cash & Current Investments at $380.9 million in Q1 2026, $242.8 million in Q4 2025, and $257.8 million in Q3 2025.